Explore

Trendline Trendline
FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment

FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment

FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment
Trendline Trendline
SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions

SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions

SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions
Trendline Trendline
North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035

North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035

North America Biotechnology Market Projected to Reach USD 2168.91 Billion by 2035
Trendline Trendline
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Trendline Trendline
Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill

Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill

Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill
Trendline Trendline
NRx Pharmaceuticals Begins U.S. Manufacturing of Preservative-Free Ketamine

NRx Pharmaceuticals Begins U.S. Manufacturing of Preservative-Free Ketamine

NRx Pharmaceuticals Begins U.S. Manufacturing of Preservative-Free Ketamine
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
Cytokinetics Reports Positive Results from Phase 3 Trial of Aficamten for Non-Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Reports Positive Results from Phase 3 Trial of Aficamten for Non-Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Reports Positive Results from Phase 3 Trial of Aficamten for Non-Obstructive Hypertrophic Cardiomyopathy
Trendline Trendline
Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026